All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

REVIVE trial: Updated results investigating efficacy and safety of rusfertide in patients with PV

Mar 20, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in polycythemia vera.

Bookmark this article

Rusfertide, a novel hepcidin mimetic peptide, has been shown to decrease serum iron levels in healthy individuals, which suggests it may help decrease erythropoiesis in patients with polycythemia vera (PV).1 The three-part phase II REVIVE trial (NCT04057040), previously reported by the MPN Hub, is an ongoing study evaluating the safety and efficacy of rusfertide in patients with phlebotomy-dependent PV.

Recently, Kremyanskaya et al.1 published updated results from Parts 1 and 2 in the New England Journal of Medicine, which are summarized below.

Study design1

  • Part 1 of the trial was a 28-week, open-label, dose-finding period where rusfertide was added to patients’ ongoing therapy.
  • Part 2 of the trial was a 12-week, double-blind, randomized withdrawal period where patients were randomized 1:1 to receive either rusfertide or placebo.
  • The primary endpoint was a response during the randomized withdrawal period.
    • Response was defined as hematocrit control, no phlebotomy, and completion of the 12-week regimen.

Key findings1

  • In total, 70 patients were enrolled in Part 1 and 59 patients in Part 2.
  • During Part 1 the need for phlebotomy decreased in all patients after rusfertide treatment.
    • The mean phlebotomy rate decreased from 8.7 during the 28-weeks before the first rusfertide dose to 0.6 after the 28-week treatment period.
    • In total, 83% of patients responded to treatment.
  • In Part 2 of the trial, a higher proportion of patients treated with rusfertide achieved a response and did not require phlebotomy vs placebo (Table 1).

Table 1. REVIVE trial Part 2 endpoints*

Part 2 endpoint (% unless otherwise stated)

Rusfertide (n = 30)

Placebo (n = 29)

p value

Response rate




Patients requiring no phlebotomy




Mean absolute change in HCT from baseline (absolute percentage point)




Median time to loss of response (weeks)

Not reached



Median time until phlebotomy requirement and first HCT above 45% (weeks)




HCT, hematocrit.
*Adapted from Kremyanskaya, et al.1

  • All patients across Parts 1 and 2 experienced ≥ 1 adverse event (AE)
  • In Part 2, more patients experienced Grade 3 AEs in the placebo group vs in the rusfertide group (9 patients vs 0 patients).
  • Injection site reactions were the most common AE; however, all were Grade 1/2 in severity.
  • All serious AEs were consistent with PV diagnosis and underlying coexisting conditions.
  • There were no clinically significant abnormal safety findings identified.

Key learnings

  • Results from the first two parts of the REVIVE trial highlight the potential of rusfertide to achieve and sustain hematocrit control, and reduce both the need for phlebotomy and occurrence of disease-related symptoms in patients with PV.
  • The third part of this trial, an open-label extension period, as well as the phase III VERIFY trial (NCT05210790), are currently ongoing to understand whether rusfertide maintains response.
  • Additional trials should focus on the impact of rusfertide on incidence of thrombotic events to further establish the role of this therapy in the therapeutic landscape.

  1. Kremyanskaya M, Kuykendall A, Pemmarju N, et al. Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera. N Engl J Med. 2024;390:723– DOI: 10.1056/NEJMoa2308809


Subscribe to get the best content related to MPN delivered to your inbox